Scenarios that move PFE
Pfizer, Inc. Common Stock
Scenarios that move PFE: 46 analyses, 10 positive, 36 negative.
- · Ascendis Pharma receives positive CHMP opinion for TransCon CNP — ▼ · impact -30 · confidence low · horizon quarters
- · FDA expands ImmunityBio's Anktiva label for bladder cancer — ▼ · impact -12 · confidence low · horizon quarters
- · RARE's Fayuvi approval triggers second $203 million PRV sale — ▼ · impact -41 · confidence low · horizon weeks
- · J&J beats Q3 earnings estimates, misses sales and raises outlook — ▼ · impact -11 · confidence low · horizon weeks
- · UnitedHealth tops estimates, raises profit outlook despite high medical costs — ▼ · impact -25 · confidence low · horizon weeks
- · ◇ What if… Iran reaches Hormuz agreement as Democrats win Senate — ▼ · impact -55 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▼ · impact -20 · confidence low · horizon quarters
- · ◇ What if… Democrats win Michigan Senate race in 2026 — ▼ · impact -51 · confidence medium · horizon quarters
- · ◇ What if… Édouard Philippe wins France’s 2027 presidential election — ▼ · impact -45 · confidence low · horizon quarters
- · HALO wins court order blocking Merck's European Keytruda SC — ▼ · impact -30 · confidence low · horizon weeks
- · Pacira BioSciences shares skyrocket in today's trading — ▼ · impact -30 · confidence low · horizon quarters
- · Bavarian Nordic raises 2026 outlook after strong Travel Health results — ▲ · impact +25 · confidence low · horizon quarters
- · SRX Global SPV agrees to acquire CERo Therapeutics — ▼ · impact -45 · confidence low · horizon quarters
- · Vaxcyte prices concurrent stock, warrant and convertible note offerings — ▼ · impact -29 · confidence medium · horizon quarters
- · ◇ What if… Plague outbreak in Russia continues and spreads further — ▲ · impact +48 · confidence medium · horizon immediate
- · Novartis acquires Abogen in $7.8B RNA therapeutics deal — ▼ · impact -35 · confidence low · horizon quarters
- · ◇ What if… Democrats win Kansas Senate race in 2026 — ▼ · impact -47 · confidence medium · horizon quarters
- · ◇ What if… Democrats win South Carolina Senate race in 2026 — ▼ · impact -48 · confidence medium · horizon quarters
- · Liquidia stock plunges 57% after UTHR patent setback — ▲ · impact +20 · confidence low · horizon weeks
- · United Therapeutics stock rises 12.6% in trading — ▼ · impact -13 · confidence medium · horizon quarters
- · ◇ What if… Republicans win Ohio Senate race in 2026 — ▲ · impact +45 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▼ · impact -25 · confidence high · horizon weeks
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▼ · impact -31 · confidence medium · horizon weeks
- · Lilly reports strong weight loss results for new drug — ▼ · impact -43 · confidence low · horizon weeks
- · DBV Technologies files FDA BLA for VIASKIN Peanut patch — ▼ · impact -25 · confidence low · horizon quarters
- · Mirum's Brelovitug meets goal in Phase III AZURE-1 study — ▼ · impact -28 · confidence low · horizon quarters
- · ◇ What if… Jean-Luc Mélenchon wins France’s 2027 presidential election — ▲ · impact +25 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -26 · confidence medium · horizon weeks
- · Pentagon awards RTX's Raytheon $20.7 billion AMRAAM contract — ▼ · impact -20 · confidence low · horizon quarters
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -46 · confidence medium · horizon quarters
- · ADARx Pharmaceuticals prices upsized $446.3 million initial public offering — ▼ · impact -35 · confidence low · horizon quarters
- · Ionis reports positive late-stage results for two partnered drugs — ▼ · impact -46 · confidence medium · horizon quarters
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +60 · confidence medium · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▲ · impact +40 · confidence low · horizon weeks
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▼ · impact -25 · confidence medium · horizon weeks
- · CHMP backs CORT's Lifyorli combo for ovarian cancer — ▲ · impact +8 · confidence low · horizon quarters
- · ◇ What if… Mary Peltola wins Alaska’s 2026 Senate race — ▼ · impact -22 · confidence low · horizon quarters
- · ◇ What if… Xavier Becerra wins California’s 2026 governor election — ▼ · impact -45 · confidence low · horizon quarters
- · Definium reports second Phase III success in anxiety program — ▼ · impact -19 · confidence medium · horizon quarters
- · ◇ What if… Mitch McConnell steps down from Senate before term ends — ▼ · impact -55 · confidence low · horizon quarters
- · Ascendis announces planned $400 million share repurchase program — ▼ · impact -24 · confidence medium · horizon quarters
- · AstraZeneca's Etcamah fails late-stage study in first-line breast cancer — ▲ · impact +35 · confidence high · horizon quarters
- · ◇ What if… Democrats win control of Senate and House after 2026 midterms — ▼ · impact -54 · confidence high · horizon quarters
- · ◇ What if… David Lisnard wins France’s 2027 presidential election — ▲ · impact +35 · confidence low · horizon quarters
- · ◇ What if… Democrats win control of the House after 2026 midterm elections — ▼ · impact -51 · confidence medium · horizon quarters
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▼ · confidence low